Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,342
Distinct drugs
373
Records naming a cancer
982
Dated in the last 12 months
177
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 42 | Sep 22, 2026 |
| EMA | EU | 461 | 246 | 386 | 75 | 20 | Sep 18, 2026 |
Data updated 2 days agoSource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Oct 19, 2006 | Imatinib | FDA US | cancer not stated in this record | Efficacy supplement 2006-10-19 (see label) | SUPPLNDA021588 | approved | openfda |
| Oct 19, 2006 | Imatinib | FDA US | cancer not stated in this record | Efficacy supplement 2006-10-19 (see label) | SUPPLNDA021588 | approved | openfda |
| Oct 17, 2006 | Docetaxel | FDA US | cancer not stated in this record | Efficacy supplement 2006-10-17 (see label) | SUPPLNDA020449 | approved | openfda |
| Oct 11, 2006 | Bevacizumab | FDA US | cancer not stated in this record | Efficacy supplement 2006-10-11 (see label) | SUPPLBLA125085 | approved | openfda |
| Oct 6, 2006 | Vorinostat | FDA US | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | ZOLINZA ® is indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive,… | ORIGNDA021991 | approved | openfda |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Aug 31, 2006 | Paclitaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as ABRAXANE FOR INJECTABLE SUSPENSION (DIN 02281066) under ATC L01CD01 PACLITAXEL. Indications are not published in the… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jul 31, 2006 | Sorafenib | Health Canada CA | cancer not stated in this record | Marketed in Canada as NEXAVAR (DIN 02284227) under ATC L01EX02 SORAFENIB. Indications are not published in the Drug Product Database — see… | DIN02284227 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jun 29, 2006 | Lenalidomide | FDA US | cancer not stated in this record | Efficacy supplement 2006-06-29 (see label) | SUPPLNDA021880 | approved | openfda |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| May 30, 2006 | Interferon Beta-1a | Health Canada CA | cancer not stated in this record | Marketed in Canada as REBIF (DIN 02277492) under ATC L03AB07 INTERFERON BETA-1A. Indications are not published in the Drug Product Database… | DIN02277492 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 11, 2006 | Mitoxantrone | FDA US | cancer not stated in this record | Mitoxantrone injection, USP (concentrate) is indicated for reducing neurologic disability and/or the frequency of clinical relapses in… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Mar 28, 2006 | Mitoxantrone | Health Canada CA | cancer not stated in this record | Marketed in Canada as MITOXANTRONE INJECTION (DIN 02267535) under ATC L01DB07 MITOXANTRONE. Indications are not published in the Drug… | DIN02267535 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jan 26, 2006 | Sunitinib | FDA US | cancer not stated in this record | treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. •… | ORIG |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.
| Sep 29, 2006 | Rituximab | FDA US | cancer not stated in this record | Efficacy supplement 2006-09-29 (see label) | SUPPLBLA103705 | approved | openfda |
| Sep 27, 2006 | Panitumumab | FDA US | Malignant Colorectal Neoplasm | Vectibix is an epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of: Adult patients with wild-type RAS… | ORIGBLA125147 | approved | openfda |
| Sep 27, 2006 | Imatinib Mesylate | FDA US | cancer not stated in this record | Efficacy supplement 2006-09-27 (see label) | SUPPLNDA021588 | approved | openfda |
| Sep 27, 2006 | Imatinib | FDA US | cancer not stated in this record | Efficacy supplement 2006-09-27 (see label) | SUPPLNDA021588 | approved | openfda |
| approvedsource: Marketed |
| health-canada-dpd |
| Aug 2, 2006 | Anagrelide | Health Canada CA | cancer not stated in this record | Marketed in Canada as DOM-ANAGRELIDE (DIN 02281287) under ATC L01XX35 ANAGRELIDE. Indications are not published in the Drug Product… | DIN02281287 | withdrawnsource: Cancelled Post Marketsince May 9, 2025 | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Jul 24, 2006 | Pegaspargase | FDA US | cancer not stated in this record | Efficacy supplement 2006-07-24 (see label) | SUPPLBLA103411 | approved | openfda |
| Jul 21, 2006 | Bicalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as PHL-BICALUTAMIDE (DIN 02281163) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product… | DIN02281163 | withdrawnsource: Cancelled Post Marketsince Jul 21, 2006 | health-canada-dpd |
| Jul 21, 2006 | Anagrelide | Health Canada CA | cancer not stated in this record | Marketed in Canada as PHL-ANAGRELIDE (DIN 02281155) under ATC L01XX35 ANAGRELIDE. Indications are not published in the Drug Product… | DIN02281155 | withdrawnsource: Cancelled Post Marketsince Oct 26, 2009 | health-canada-dpd |
| Jul 19, 2006 | Sorafenib | EMA EU | cancer not stated in this record | Hepatocellular carcinoma Nexavar is indicated for the treatment of hepatocellular carcinoma. Renal cell carcinoma Nexavar is indicated for… | centralisedEMEA/H/C/000690 | approved | ema |
| Jul 19, 2006 | Sunitinib | EMA EU | cancer not stated in this record | Gastrointestinal stromal tumour (GIST) Sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal… | centralisedEMEA/H/C/000687 | approved | ema |
| Jul 14, 2006 | Histrelin | Health Canada CA | cancer not stated in this record | Marketed in Canada as VANTAS (DIN 02278383) under ATC L02AE05 HISTRELIN. Indications are not published in the Drug Product Database — see… | DIN02278383 | withdrawnsource: Cancelled Post Marketsince Apr 7, 2017 | health-canada-dpd |
| Jun 28, 2006 | Dasatinib | FDA US | cancer not stated in this record | Dasatinib tablets are indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic… | ORIGNDA021986 | approved | openfda |
| Jun 22, 2006 | Sunitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as SUTENT (DIN 02280817) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see… | DIN02280817 | approvedsource: Marketed | health-canada-dpd |
| Jun 22, 2006 | Sunitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as SUTENT (DIN 02280809) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see… | DIN02280809 | approvedsource: Marketed | health-canada-dpd |
| Jun 22, 2006 | Sunitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as SUTENT (DIN 02280795) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see… | DIN02280795 | approvedsource: Marketed | health-canada-dpd |
| Jun 20, 2006 | Bevacizumab | FDA US | cancer not stated in this record | Efficacy supplement 2006-06-20 (see label) | SUPPLBLA125085 | approved | openfda |
| Jun 19, 2006 | Interferon Beta-1a | Health Canada CA | cancer not stated in this record | Marketed in Canada as REBIF (DIN 02281708) under ATC L03AB07 INTERFERON BETA-1A. Indications are not published in the Drug Product Database… | DIN02281708 | withdrawnsource: Cancelled Post Marketsince Aug 9, 2013 | health-canada-dpd |
| Jun 14, 2006 | Topotecan | FDA US | cancer not stated in this record | Efficacy supplement 2006-06-14 (see label) | SUPPLNDA020671 | approved | openfda |
| Jun 2, 2006 | Sirolimus | FDA US | cancer not stated in this record | Efficacy supplement 2006-06-02 (see label) | SUPPLNDA021083 | approved | openfda |
| Jun 2, 2006 | Sirolimus | FDA US | cancer not stated in this record | Efficacy supplement 2006-06-02 (see label) | SUPPLNDA021110 | approved | openfda |
| Jun 1, 2006 | Prednisolone | FDA US | cancer not stated in this record | Allergic Conditions Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in… | ORIGNDA021959 | approved | openfda |
| Jun 1, 2006 | Prednisolone | FDA US | Mycosis Fungoides | Dermatologic Diseases Bullous dermatitis herpetiformis Contact dermatitis Exfoliative erythroderma Mycosis fungoides Pemphigus Severe… | ORIGNDA021959 | approved | openfda |
| withdrawnsource: Cancelled Post Marketsince Aug 9, 2013 |
| health-canada-dpd |
| May 29, 2006 | Clofarabine | EMA EU | Acute Lymphoblastic Leukemia | Treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients who have relapsed or are refractory after receiving at least two… | centralisedEMEA/H/C/000613 | approved | ema |
| ORIGANDA077356 |
| approved |
| openfda |
| Apr 10, 2006 | Tositumomab | Health Canada CA | cancer not stated in this record | Marketed in Canada as BEXXAR THERAPY (DIN 02270471) under ATC V10XA53 TOSITUMOMAB/IODINE (131 I) TOSITUMOMAB. Indications are not published… | DIN02270471 | withdrawnsource: Cancelled Post Marketsince Jul 31, 2014 | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Jul 9, 2018 |
| health-canada-dpd |
| Mar 22, 2006 | Docetaxel | FDA US | cancer not stated in this record | Efficacy supplement 2006-03-22 (see label) | SUPPLNDA020449 | approved | openfda |
| Mar 13, 2006 | Bicalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as RATIO-BICALUTAMIDE (DIN 02277700) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product… | DIN02277700 | withdrawnsource: Cancelled Post Marketsince Sep 19, 2014 | health-canada-dpd |
| Mar 1, 2006 | Cetuximab | FDA US | cancer not stated in this record | Efficacy supplement 2006-03-01 (see label) | SUPPLBLA125084 | approved | openfda |
| Mar 1, 2006 | Cetuximab | FDA US | cancer not stated in this record | Efficacy supplement 2006-03-01 (see label) | SUPPLBLA125084 | approved | openfda |
| Feb 10, 2006 | Rituximab | FDA US | cancer not stated in this record | Efficacy supplement 2006-02-10 (see label) | SUPPLBLA103705 | approved | openfda |
| Feb 10, 2006 | Bicalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-BICALUTAMIDE (DIN 02270226) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product… | DIN02270226 | approvedsource: Marketed | health-canada-dpd |
| Feb 8, 2006 | Bicalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as SANDOZ BICALUTAMIDE (DIN 02276089) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product… | DIN02276089 | withdrawnsource: Cancelled Post Marketsince Aug 1, 2019 | health-canada-dpd |
| Feb 8, 2006 | Bicalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as PMS-BICALUTAMIDE (DIN 02275589) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product… | DIN02275589 | approvedsource: Marketed | health-canada-dpd |
| Feb 7, 2006 | Bicalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as ACT BICALUTAMIDE (DIN 02274337) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product… | DIN02274337 | withdrawnsource: Cancelled Post Marketsince Jul 11, 2018 | health-canada-dpd |
| Feb 1, 2006 | Irinotecan | Health Canada CA | cancer not stated in this record | Marketed in Canada as IRINOTECAN HYDROCHLORIDE INJECTION USP (DIN 02258218) under ATC L01CE02 IRINOTECAN. Indications are not published in… | DIN02258218 | approvedsource: Marketed | health-canada-dpd |
| approved |
| openfda |
| Jan 26, 2006 | Sunitinib | FDA US | Primitive Neuroectodermal Tumor | treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced… | ORIGNDA021938 | approved | openfda |
| Jan 26, 2006 | Sunitinib | FDA US | Renal Cell Carcinoma | treatment of adult patients with advanced renal cell carcinoma (RCC). | ORIGNDA021938 | approved | openfda |